Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 01:10 ET | Source: Clinuvel Pharmaceuticals Limited

SCENESSE® approved for EPP in Canada

MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of...
October 28, 2021 07:30 ET | Source: Roots Analysis

The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis

London, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare...
April 16, 2020 02:53 ET | Source: Clinuvel Pharmaceuticals Limited

Innovative drug launched for rare, isolating, “light intolerance” disorder

MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...
July 06, 2016 08:00 ET | Source: Clinuvel Pharmaceuticals Limited

US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP

FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...